7-5987568-C-T
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6_Very_StrongBP7
The NM_000535.7(PMS2):c.1197G>A(p.Lys399Lys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000183 in 1,612,978 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_000535.7 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152110Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000723 AC: 18AN: 248826Hom.: 0 AF XY: 0.0000592 AC XY: 8AN XY: 135230
GnomAD4 exome AF: 0.000198 AC: 289AN: 1460868Hom.: 0 Cov.: 33 AF XY: 0.000195 AC XY: 142AN XY: 726762
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152110Hom.: 0 Cov.: 31 AF XY: 0.0000404 AC XY: 3AN XY: 74304
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:4
- -
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
not provided Benign:3
- -
The c.1197G>A; p.Lys399Lys variant (rs757730609) does not alter the amino acid sequence of the PMS2 protein and computational splice site prediction algorithms do not predict a change in the nearest splice site or creation of a cryptic splice site. This variant has not been reported in association with any hereditary cancer syndromes in the medical literature or in gene specific variation databases. This variant is listed in the Genome Aggregation Database (gnomAD) with a frequency of 0.02 percent in the European Non-Finnish population (identified on 19 out of 125,472 chromosomes), and has been reported to the ClinVar database as a likely benign variant (Variation ID: 184060). Based on these observations, the p.Lys399Lys variant is likely to be benign. -
PMS2: BP4, BP7 -
not specified Benign:1
- -
Breast and/or ovarian cancer Benign:1
- -
Lynch syndrome Benign:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Malignant tumor of breast Benign:1
The PMS2 p.Lys399= variant was not identified in the literature. The variant was identified in dbSNP (ID: rs757730609) as “With Uncertain significance allele”, ClinVar (as likely benign by Ambry Genetics, Invitae, Color Genomics, ARUP Laboratories, and True Health Diagnostics, and as uncertain significacne by Integrated Genetics . The variant was identified in control databases in 19 of 275194 chromosomes at a frequency of 0.000069 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (Non-Finnish) in 19 of 125472 chromosomes (freq: 0.000151), while the variant was not observed in the African, Other, Latino, Ashkenazi Jewish, East Asian, European (Finnish), and South Asian populations. The p.Lys399= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at